Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Goals in the Treatment of Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.

Factors When Weighing Intensive Chemotherapy vs Other Regimens in Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.

Dose Intensity and Sequencing of Intensive Chemotherapy in Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.

Long-Term Data for CPX-351 in Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.

Defining Intensive Chemotherapy Fitness in AML

October 24th 2024

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.

The Diagnosis and Prevalence of Secondary AML

October 24th 2024

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.

NX-5948 Generates Responses in R/R Waldenström Macroglobulinemia

October 22nd 2024

Treatment with the BTK degrader NX-5948 led to responses in patients with relapsed/refractory Waldenström macroglobulinemia.

Dr Battiwalla on the Potential Roles of FLT3-ITD and Menin Inhibitors in AML Management

October 21st 2024

Minoo Battiwalla, MD, MS, discusses the potential of FLT3-ITD and menin inhibitors to broaden the acute myeloid leukemia treatment paradigm.

New Global Hematology Journal Strives to Feature Innovative and Adaptable Research

October 21st 2024

Jorge Cortes, MD, inaugural editor-in-chief of Blood Global Hematology, details what type of research the new journal will highlight and its importance.

Asciminib Yields Promising Efficacy vs SOC Agents in CML

October 17th 2024

Jorge Cortes, MD, details how asciminib could affect care for patients with CML, diving into key takeaways from the ASC4FIRST trial.

Donor Clonal Hematopoiesis May Predict Post-Transplant Relapse and Outcomes in Hematologic Malignancies

October 16th 2024

Screening for donor-derived clonal hematopoiesis may have prognostic value for outcomes following auto-HSCT in patients with hematologic malignancies.

Galinpepimut-S Earns FDA Rare Pediatric Disease Designation for AML

October 16th 2024

The FDA has granted rare pediatric disease designation to galinpepimut-S for acute myeloid leukemia.

VIP943 Generates Early Complete Responses, Is Safe in Advanced CD123+ Hematologic Malignancies

October 11th 2024

Complete responses were achieved by 2 patients with advanced CD123-positive hematologic malignancies who received VIP943 in a phase 1 study.

Menin Inhibitors for AML: A Roundtable on the Latest Advances

October 10th 2024

Justin Kaner, MD, discusses the latest advances surrounding menin inhibitors in acute myeloid leukemia.

NT-I7 After CAR T-Cell Therapy Enhances CAR T Factors in R/R DLBCL

October 7th 2024

NT-I7 with CAR T-cell therapy demonstrated an 81.1% objective response rate in relapsed DLBCL patients and a manageable safety profile.

ELVN-001 Appears Safe and Effective in Relapsed/Refractory CML

October 7th 2024

ELVN-001 generated prolonged signals of clinical activity with a tolerable safety profile in patients with TKI-relapsed, -refractory, or -intolerant CML.

The OncFive: Top Oncology Articles for the Week of 9/29

October 5th 2024

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

Ribaxamase Shows Safety in the Prevention of aGVHD Following Allo-HSCT

October 3rd 2024

A committee recommended a phase 1/2 study of ribaxamase for the prevention of acute graft-vs-host-disease proceed with enrollment for a third cohort.

Dr Battiwalla on the Expanding Use of Bispecific Antibodies in NHL

September 27th 2024

Minoo Battiwalla, MD, MS, discusses the variety of bispecific antibodies evaluated for patients with NHL, including DLBCL.

Meta-Analysis Reveals Potential Role of Clonal Hematopoiesis on Allogeneic and Autologous HSCT Outcomes

September 27th 2024

Shyam A. Patel, MD, PhD, discusses findings from a meta-analysis of the effect of clonal hematopoiesis on outcomes for hematopoietic stem cell transplant.